Bevixa 100 mg/4 ml
- Generic
- Bevacizumab
- Manufacturer
- Incepta Pharmaceuticals Ltd.
- Drug class
- Targeted Cancer Therapy
- Pregnancy category
- C
Price
৳20,000 per 100 mg vial
Packs & prices
- 100 mg vial৳20,000
This is information only. Do not start, stop or switch medicines without a doctor's advice.
Warnings
Contraindications
Precautions
Side effects
Pregnancy & lactation
Drug interactions
In a randomized study in 99 patients with NSCLC, based on limited data, there did not appear to be a difference in the mean exposure of either carboplatin or paclitaxel when each was administered alone or in combination with Bevacizumab. However, 3 of the 8 patients receiving Bevacizumab plus paclitaxel/carboplatin had substantially lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at Day 0, while patients receiving paclitaxel/carboplatin without Bevacizumab had a greater paclitaxel exposure at Day 63 than at Day 0.
More information
Indications
- Metastatic Colorectal Cancer (mCRC)
- Non-Squamous Non–Small Cell Lung Cancer (NSCLC)
- Glioblastoma
- Metastatic Renal Cell Carcinoma (mRCC)
- Persistent, Recurrent, or Metastatic Carcinoma of the Cervix
- Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Dosage
- Administer 5 mg/kg when used in combination with bolus-IFL.
- Administer 10 mg/kg when used in combination with FOLFOX4.
- Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Bevacizumab-containing regimen.
Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks.
Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa.
Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.
Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10mg/ kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks).
Administration
First infusion: Administer infusion over 90 minutes. Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated; administer all subsequent infusions over 30 minutes if infusion over 60 minutes is tolerated.
Use in children
Antitumor activity was not observed among eight children with relapsed glioblastoma treated with Bevacizumab and irinotecan. There is insufficient information to determine the safety and efficacy of Bevacizumab in children with glioblastoma.
Overdose
Pharmacology
Therapeutic class
Reconstitution
Storage
Source: medex.com.bd · Prescribing information (PDF)
Cheaper alternatives
Same generic, strength and form — sorted by price
BevacimabCheapest
Healthcare Pharmaceuticals Ltd.
৳16,100 / 100 mg vial
৳3,900 less (20%)
Bevastim
Beacon Pharmaceuticals Ltd.
৳18,560 / 100 mg vial
৳1,440 less (7%)
Avastin
Roche Bangladesh Ltd.
৳20,200 / 100 mg vial
৳200 more
Bottle/tube prices depend on size — compare quantities before switching.